<DOC>
	<DOCNO>NCT03075462</DOCNO>
	<brief_summary>Fluzoparib oral potent , selective poly-ADP ribose polymerase-1 ( PARP-1 ) PARP-2 inhibitor ; Apatinib oral selective vascular endothelial growth factor receptor ( VEGFR ) inhibitor . This open-label , dose find phase I trial study tolerability best dose fluzoparib combination apatinib see well two drug work together treatment patient recurrent ovarian cancer triple negative breast cancer . The safety efficacy fluzoparib combination apatinib explore . Both dose escalation dose expansion part include study .</brief_summary>
	<brief_title>A Study Fluzoparib Given Combination With Apatinib Ovarian Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Life expectancy 12 week . Histologically cytologically confirm highgrade papillaryserous epithelial ovarian cancer，primary peritoneal , fallopian tube cancer ; subject know deleterious breast cancer gene ( BRCA ) mutation highgrade histology also eligible . Subjects platinumsensitive disease , platinumsensitive disease define &gt; 6 month interval since last receiving platinum therapy prior disease recurrence . Additionally , subject histologically cytologically confirm triple negative breast cancer ( TNBC） , locally advanced metastatic , also eligible . Prior therapy：subjects ovarian cancer，primary peritoneal , fallopian tube cancer receive 2 line platinumbased chemotherapy , TNBC patient receive 1 line standard chemotherapy . Each prior chemotherapy must give least 2 cycle . At least one measurable lesion accurately assess imaging ( CT/MRI ) baseline Subjects overall good overall general condition . Signed informed consent . Subjects receive previous treatment PARP inhibitor . Subjects receive previous treatment VEGFR inhibitor . Less 4 week last clinical trial . Less 4 week last radiotherapy , chemotherapy , surgery , hormone treatment target therapy . Unstable uncontrolled hypertension . Subjects unable swallow , dysfunction gastrointestinal absorption . Subjects brain metastasis . Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects know hypersensitivity fluzoparib , apatinib excipients product . Ongoing infection ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Pregnant breastfeed woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PARP inhibitor</keyword>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
</DOC>